Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Interferon-γ-Inducible Chemokines as Prognostic Markers for Lung Cancer.

Tytuł:
Interferon-γ-Inducible Chemokines as Prognostic Markers for Lung Cancer.
Autorzy:
Lee KS; Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea.
Chung WY; Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea.
Park JE; Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea.
Jung YJ; Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea.
Park JH; Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea.
Sheen SS; Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea.
Park KJ; Department of Pulmonology and Critical Care Medicine, Ajou University School of Medicine, Suwon 16499, Korea.
Źródło:
International journal of environmental research and public health [Int J Environ Res Public Health] 2021 Sep 04; Vol. 18 (17). Date of Electronic Publication: 2021 Sep 04.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel : MDPI, c2004-
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*
Chemokines, C*
Lung Neoplasms*
Chemokine CXCL10 ; Humans ; Interferon-gamma ; Interferons ; Prognosis
References:
J Interferon Cytokine Res. 2019 Jan;39(1):30-38. (PMID: 30388040)
J Immunol. 2009 Jun 1;182(11):6951-8. (PMID: 19454692)
Eur J Immunol. 2019 Aug;49(8):1147-1152. (PMID: 31270810)
Anticancer Res. 2016 Nov;36(11):5593-5606. (PMID: 27793882)
J Urol. 2014 Aug;192(2):567-74. (PMID: 24518777)
Lung Cancer. 2002 Sep;37(3):271-6. (PMID: 12234695)
PLoS One. 2013 Nov 21;8(11):e80052. (PMID: 24278236)
J Natl Cancer Inst. 2015 Jul 28;107(10):. (PMID: 26220734)
Front Immunol. 2018 Jan 15;8:1970. (PMID: 29379506)
Oncotarget. 2016 Mar 22;7(12):14405-14. (PMID: 26883105)
Mol Cancer Ther. 2009 Mar;8(3):490-8. (PMID: 19276169)
Int J Oncol. 2012 Feb;40(2):560-6. (PMID: 22038159)
Anticancer Res. 2015 Dec;35(12):6979-83. (PMID: 26637925)
Carcinogenesis. 2011 Feb;32(2):129-37. (PMID: 21051441)
Oncogene. 2007 Jul 12;26(32):4679-88. (PMID: 17297455)
Gynecol Oncol. 2011 Sep;122(3):648-55. (PMID: 21684584)
Front Immunol. 2018 Sep 25;9:2159. (PMID: 30319622)
Oral Oncol. 2013 Aug;49(8):802-7. (PMID: 23769451)
N Engl J Med. 2012 Jun 28;366(26):2443-54. (PMID: 22658127)
Int J Gynecol Cancer. 2014 Jul;24(6):1085-92. (PMID: 24905620)
Int J Tuberc Lung Dis. 2015 Feb;19(2):191-9. (PMID: 25574918)
Chest. 2017 Jan;151(1):193-203. (PMID: 27780786)
Cancer. 2017 Jan 1;123(1):144-154. (PMID: 27529817)
J Thorac Dis. 2017 Apr;9(Suppl 3):S164-S171. (PMID: 28446981)
Immunology. 2014 Sep;143(1):109-19. (PMID: 24679047)
Cancer Treat Rev. 2018 Feb;63:40-47. (PMID: 29207310)
J Biol Chem. 2014 Feb 7;289(6):3126-37. (PMID: 24366869)
Clin Cancer Res. 2013 Jan 15;19(2):336-46. (PMID: 23213058)
Exp Cell Res. 2011 Mar 10;317(5):620-31. (PMID: 21376175)
Int J Tuberc Lung Dis. 2015 Dec;19(12):1476-84. (PMID: 26614189)
Cent Eur J Immunol. 2016;41(4):358-362. (PMID: 28450798)
Oncotarget. 2018 Apr 3;9(25):17928-17936. (PMID: 29707158)
Nat Rev Immunol. 2017 Sep;17(9):559-572. (PMID: 28555670)
Reproduction. 2012 Sep;144(3):303-17. (PMID: 22771929)
Leuk Lymphoma. 2016 Nov;57(11):2516-25. (PMID: 26999330)
Contributed Indexing:
Keywords: CXCR3 ligand; biomarker; cell-mediated immunity; interferon-γ; lung cancer; prognosis
Substance Nomenclature:
0 (Chemokine CXCL10)
0 (Chemokines, C)
82115-62-6 (Interferon-gamma)
9008-11-1 (Interferons)
Entry Date(s):
Date Created: 20210910 Date Completed: 20211025 Latest Revision: 20211025
Update Code:
20240105
PubMed Central ID:
PMC8431216
DOI:
10.3390/ijerph18179345
PMID:
34501934
Czasopismo naukowe
Interferon (IFN)-γ-inducible chemokines in the CXCR3/ligand axis are involved in cell-mediated immunity and play a significant role in the progression of cancer. We enrolled patients with lung cancer ( n = 144) and healthy volunteers as the controls ( n = 140). Initial blood samples were collected and concentrations of IFN-γ and IFN-γ-inducible chemokines CXCL9, CXCL10, and CXCL11 were measured using enzyme-linked immunosorbent assay. Of patients with lung cancer, 125 had non-small cell lung cancer (NSCLC) and 19 had small cell lung cancer. The area under the curve (AUC) (95% CI) of CXCL9 was 0.83 (0.80-0.89) for differentiating lung cancer patients from controls. The levels of all the markers were significantly higher in NSCLC patients with stage IV than in those with stages I-III. A Kaplan-Meier survival analysis showed that NSCLC cancer patients with higher levels of all markers showed poorer survival than those with lower levels. In Cox multivariate analysis of patients with NSCLC, independent prognostic factors for overall survival were CXCL9 and CXCL11. CXCL9 was the only independent prognostic factor for cancer-specific survival. Serum IFN-γ-inducible chemokines may be useful as clinical markers of metastasis and prognosis in NSCLC, and CXCL9 levels showed the most significant results.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies